more accurate and prompt responses.
REPORT | T&R Biofab Signs Agreement for Exclusive Distribution of Orbital Patient- Specific Implants | DATE : 2023.02.28 | VIEW : 1774 |
---|---|---|---|
- A biodegradable product customized to individual patients by 3D printer -
T&R Biofab (246710, CEO Won-soo Yun), a company specializing in regenerative medicine, announced that it has signed a supply agreement with Johnson & Johnson Medical Korea, for its 3D bioprinted patient-customized implant products (Product name: TnR PSI Plus, T&R PSI Plus).
'T&R PSI Plus' is a patient-specific implant (PSI) for patients with fractures and injuries in the maxillofacial region. The core materials are PCL (polycaprolactone), a US FDA-approved biodegradable polymer, and Beta-TCP (beta-tricalcium phosphate), both well-documented in various clinical applications and case studies for their safety, biocompatibility, biodegradability, and in inducing new bone growth as well as other tissues, like cartilage.
‘T&R PSI Plus’ is a customized implant optimized for each patient's injury site specifications, designed using the patient's derived CT data and manufactured using ultra-precise 3D bioprinting technology. The implant is designed to capture complex defects and anatomical features, reducing unnecessary manipulations in the bone during surgery and providing a better fit and comfort for the patient. Since the product launch in 2014, surgeons have attested to its benefits in improving surgical accuracy and shortening surgery time. In addition, the biodegradable nature of the implant associated to its gradual replacement by the patient’s own tissue, in other words, autologous tissue, greatly reduces the risk of long-term side effects associated with traditional implants, such as severe inflammatory responses.
"We are very pleased with the recognition of our technology and product quality. It is of great significance that we have signed the first supply contract of PSI" said Dr. Won-soo Yun, CEO of T&R Biofab.
T&R Biofab received a Level 4 medical device license from the Ministry of Food and Drug Administration in 2014 for T&R PSI Plus, and has been a trusted provider in best hospitals in Korea. Moreover, in cooperation with leading medical institutions and authorities in US, Poland, and Ukraine, T&R Biofab recently supplied ‘T&R PSI Plus’ implants as humanitarian aid to treat injured patients from the ongoing Ukraine war, contributing to life-changing treatments on a global scale.
|
Prev ▲ | Woman given a new 3D-printed windpipe in a world-first | 2024.03.08 |
Next ▼ | T&R Biofab Announces Research Collaboration for 3D Bio-printed Surgical Solution | 2022.08.12 |